Log In

 

Company Name : Replicor Inc.

Friday, April 21, 2017 8:19PM IST (2:49PM GMT)

(BW)(REPLICOR-INC.)

Replicor discloses achievement of 1 year functional control of HBV and HDV with NAPs and new mechanistic insights in NAP pharmacology


Montreal, Canada

Replicor Inc., a privately held biopharmaceutical company targeting a cure for chronic HBV and HDV infection, disclosed significant new data on NAP activity in HBV and HDV infections at the European Association for the Study of the Liver (EASL) 2017 annual meeting held April 19-23, 2017 in Amsterdam, The Netherlands.

 

Updates in the REP 301 (HBV/HDV coinfection) and REP 401 (HBV infection) studies demonstrated important advances:

 

1. In the REP 301 study, previously reported functional control at 24 weeks follow-up of HBV (5/12 patients) and HDV (7/12 patients) was shown to be maintained at one year, demonstrating the durability of functional control established with NAP based therapy (poster LBP-507).

 

2. In the REP 401 study, 30 patients have received at least 12 weeks of NAP exposure and serum HBsAg response over time continues to improve: current reductions from baseline presented were >1log in 29 patients, >2logs in 25 patients, >4logs in 19 patients, with HBsAg loss in 14 patients. Improved efficacy of pegIFN (marked anti-HBs production and/or therapeutic transaminase flares) occurred in all patients with HBsAg reduction > 4 log (poster THU-154).

 

3. Surprisingly, analysis of serum HBsAg, HBeAg, HBcrAg, HBV RNA, HBV DNA and HDV RNA in both studies indicated that circulating HBsAg appears to be almost completely derived from integration.

 

“The notion that almost all circulating HBsAg is derived from integration has important therapeutic implications,” said CSO Dr. Andrew Vaillant. “As the primary immunosuppressive agent in HBV and HDV infections, HBsAg removal will be critical. It’s very likely that new investigational agents with other antiviral mechanisms will still require agents directly targeting HBsAg release like NAPs in order to achieve a high rate of functional control.” Dr. Bazinet, CEO, added “our continually expanding clinical data continues to demonstrate that significant rates of functional control of HBV and HDV can be achieved with currently approved drugs and NAPs.”

 

Deep sequencing of HBsAg in the previous REP 102 study showed no selection pressure with REP 2139, further validating the serum HBsAg response to NAP therapy (Poster THU-155). A recently developed tissue culture system now reproduces for the first time the post-entry effects of NAPs on secretion of HBV particles observed preclinically and clinically (Poster THU-156).

 

Dr. Vaillant remarked, “The ability to model the post-entry effects of NAPs in tissue culture is the culmination of more than 6 years of work which including various collaborators worldwide. With this tool finally in place, the host mechanisms targeted by NAPs can now begin to be explored.”

 

Replicor’s presentations from EASL 2017 are now available at www.replicor.com/science/conference-presentations. For the 2017 EASL Meeting: https://ilc-congress.eu/.

 

About Replicor

 

Replicor is a privately held biopharmaceutical company with the most advanced clinical data in the development of the cure for HBV and HDV. The company is dedicated to accelerating the development of an effective treatment for patients with HBV and HBV/HDV infection. www.replicor.com

 

 

 

 


Click here for Media Contact Details
CONTACTS : Natacha Dorgetndorget@replicor.com514-733-1998

More News from Replicor Inc.

14/02/2017 12:56AM

Replicor Discloses Updated REP 401 Clinical Data at APASL 2017

Replicor Inc., a privately held biopharmaceutical company targeting a cure for chronic hepatitis B and D patients, announced that an updated interim analysis from its latest REP 401 clinical trial has been selected ...

04/10/2016 5:45PM

Replicor to Disclose Late Breaking HBV Clinical Data at AASLD 2016

Replicor Inc., a privately held biopharmaceutical company targeting a cure for chronic hepatitis B and D patients, today announced that the preliminary interim analysis from its latest REP 401 clinical trial has been ...

17/02/2016 9:13AM

Replicor to Present Pre-Clinical and Updated Clinical Data on REP 2139-Ca Based Combination Therapy in Chronic HBV and HBV / HDV Co-Infection at APASL 2016

Replicor Inc., a privately held biopharmaceutical company targeting a cure for patients with chronic hepatitis B virus (HBV) and chronic HBV and hepatitis delta virus (HDV) co-infection, will present preclinical and ...

Similar News

21/09/2017 2:50PM

Medical Tourism in Sri Lanka to Boom with the Offer of Low-cost Services and Government Support

Frost & Sullivan's "Sri Lanka Medical Tourism Industry Insights" analyses the drivers, restraints, government initiatives and growth opportunities in the medical tourism industry in Sri Lanka, and also presents a ...

No Image

20/09/2017 6:40PM

6th Annual World Patient Safety, Science & Technology Summit to Be Held in London, England

The Patient Safety Movement Foundation (PSMF) announces that the 6th Annual World Patient Safety, Science & Technology Summit will take place in London on February 23-25, 2018. Rt. Hon. Jeremy Hunt MP, the Secretary ...